Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of GlobeImmune Inc  (NASDAQ: GBIM) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of GlobeImmune Inc  (NASDAQ: GBIM)  concerning whether a series of statements by GlobeImmune Inc  regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 27, 2015, GlobeImmune Inc announced the Phase 2 trial for its hepatitis B treatment. On news that the Company’s hepatitis B treatment failed to meet the trial’s primary endpoint, GBIM shares dropped by $4.23 per share, or over 50%, to close on May 27, 2015 at $4.01 per share.

Then, on June 10, 2015, GlobeImmune stated that, “it is evaluating strategic options for the company. In conjunction with this process, the Board has authorized eliminating the majority of positions in its workforce. . . Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune.”

Following the release of this news, shares of GlobeImmune fell $1.00 per share, during intraday trading on June 10, 2015, or more than 26%.

If you purchased shares of GlobeImmune Inc  (NASDAQ: GBIM) on or before May 27, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185